DFDRNN: A dual-feature based neural network for drug repositioning
- URL: http://arxiv.org/abs/2407.11812v1
- Date: Tue, 16 Jul 2024 15:02:18 GMT
- Title: DFDRNN: A dual-feature based neural network for drug repositioning
- Authors: Enqiang Zhu, Xiang Li, Chanjuan Liu, Nikhil R. Pal,
- Abstract summary: Drug repositioning is an economically efficient strategy used to discover new indications for existing drugs beyond their original approvals.
We design a dual-feature drug repositioning neural network model to achieve precise encoding of drugs and diseases.
Compared to six state-of-the-art methods, DFDRNN outperforms others on four benchmark datasets.
- Score: 9.721502993958193
- License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
- Abstract: Drug repositioning is an economically efficient strategy used to discover new indications for existing drugs beyond their original approvals, expanding their applicability and usage to address challenges in disease treatment. In recent years, deep-learning techniques for drug repositioning have gained much attention. While most deep learning-based research methods focus on encoding drugs and diseases by extracting feature information from neighbors in the network, they often pay little attention to the potential relationships between the features of drugs and diseases, leading to imprecise encoding of drugs and diseases. To address this, we design a dual-feature drug repositioning neural network (DFDRNN) model to achieve precise encoding of drugs and diseases. DFDRNN uses two features to represent drugs and diseases: the similarity feature and the association feature. The model incorporates a self-attention mechanism to design two dual-feature extraction modules for achieving precisely encoding of drugs and diseases: the intra-domain dual-feature extraction (IntraDDFE) module and the inter-domain dual-feature extraction (InterDDFE) module. The IntraDDFE module extracts features from a single domain (drug or disease domain), while the InterDDFE module extracts features from the mixed domain (drug and disease domain). In particular, the feature is changed by InterDDFE, ensuring a precise encoding of drugs and diseases. Finally, a cross-dual-domain decoder is designed to predict drug-disease associations in both the drug and disease domains. Compared to six state-of-the-art methods, DFDRNN outperforms others on four benchmark datasets, with an average AUROC of 0.946 and an average AUPR of 0.597.
Related papers
- Learning to Describe for Predicting Zero-shot Drug-Drug Interactions [54.172575323610175]
Adverse drug-drug interactions can compromise the effectiveness of concurrent drug administration.
Traditional computational methods for DDI prediction may fail to capture interactions for new drugs due to the lack of knowledge.
We propose TextDDI with a language model-based DDI predictor and a reinforcement learning(RL)-based information selector.
arXiv Detail & Related papers (2024-03-13T09:42:46Z) - Modeling Path Importance for Effective Alzheimer's Disease Drug
Repurposing [8.153491945775734]
We propose MPI (Modeling Path Importance), a novel network-based method for AD drug repurposing.
MPI prioritizes important paths via learned node embeddings, which can effectively capture a network's rich structural information.
We observe that among the top-50 ranked drugs, MPI prioritizes 20.0% more drugs with anti-AD evidence compared to the baseline.
arXiv Detail & Related papers (2023-10-23T17:24:11Z) - Source-Free Domain Adaptation for Medical Image Segmentation via
Prototype-Anchored Feature Alignment and Contrastive Learning [57.43322536718131]
We present a two-stage source-free domain adaptation (SFDA) framework for medical image segmentation.
In the prototype-anchored feature alignment stage, we first utilize the weights of the pre-trained pixel-wise classifier as source prototypes.
Then, we introduce the bi-directional transport to align the target features with class prototypes by minimizing its expected cost.
arXiv Detail & Related papers (2023-07-19T06:07:12Z) - Knowledge-Driven New Drug Recommendation [88.35607943144261]
We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs.
EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base.
Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
arXiv Detail & Related papers (2022-10-11T16:07:52Z) - SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly.
On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
arXiv Detail & Related papers (2021-05-05T00:20:48Z) - AttentionDDI: Siamese Attention-based Deep Learning method for drug-drug
interaction predictions [0.9176056742068811]
Drug-drug interactions (DDIs) refer to processes triggered by the administration of two or more drugs leading to side effects beyond those observed when drugs are administered by themselves.
Due to the massive number of possible drug pairs, it is nearly impossible to experimentally test all combinations and discover previously unobserved side effects.
We propose a Siamese self-attention multi-modal neural network for DDI prediction that integrates multiple drug similarity measures.
arXiv Detail & Related papers (2020-12-24T13:33:07Z) - Two Step Joint Model for Drug Drug Interaction Extraction [82.49278654043577]
Drug-Drug Interaction (DDI) Extraction from Drug Labels challenge of Text Analysis Conference (TAC) 2018.
We propose a two step joint model to detect DDI and it's related mentions jointly.
A sequence tagging system (CNN-GRU encoder-decoder) finds precipitants first and search its fine-grained Trigger and determine the DDI for each precipitant in the second step.
arXiv Detail & Related papers (2020-08-28T15:30:08Z) - Hybrid Attentional Memory Network for Computational drug repositioning [0.0]
The cold start problem has always been a major challenge in the field of computational drug repositioning.
We propose the Hybrid Attentional Memory Network (HAMN) model, a deep architecture combines two classes of CF model in a nonlinear manner.
Our proposed HAMN model is superior to other comparison models according to the AUC, AUPR and HR indicators.
arXiv Detail & Related papers (2020-06-12T02:12:32Z) - Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug
Response [49.86828302591469]
In this paper, we apply transfer learning to the prediction of anti-cancer drug response.
We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset.
The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures.
arXiv Detail & Related papers (2020-05-13T20:29:48Z) - Drug-Drug Interaction Prediction with Wasserstein Adversarial
Autoencoder-based Knowledge Graph Embeddings [22.562175708415392]
We propose a new knowledge graph embedding framework for drug-drug interactions.
In our framework, the autoencoder is employed to generate high-quality negative samples.
The discriminator learns the embeddings of drugs and interactions based on both positive and negative triplets.
arXiv Detail & Related papers (2020-04-15T21:03:29Z)
This list is automatically generated from the titles and abstracts of the papers in this site.
This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.